Bavarian Nordic CEO shows no mercy to competitors as firm continues partner hunt: "If they fail, the value of our program increases"

Bavarian Nordic’s RSV vaccine candidate has been awarded priority status by both the US and EU authorities. That sends a positive signal to potential partners, says CEO Paul Chaplin.

Paul Chaplin, CEO, Bavarian Nordic

At exactly 8 o’clock this morning, Bavarian Nordic could announce that it had been granted PRIME status by the European Medicines Agency (EMA).

This entails a number of advantages for Bavarian Nordic’s RSV vaccine targeting the over-60s, including an accelerated approval process and more access to dialog and interactions with the EMA.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs